HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a master services agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for work to be performed in HTG’s VERI/O laboratory.
TUCSON, Ariz., June 23, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced the introduction of its Tucson‑based VERI/O laboratory service, offering laboratory support for its biopharma clients in biomarker research and companion diagnostic development. The VERI/O laboratory service formalizes and expands HTG’s traditional service offerings, including molecular profiling of retrospective cohorts to support development of targeted and immuno-oncology therapies, building custom research-use-only (RUO) assays to support early stage clinical programs, and developing companion diagnostic assays for use in Phase III registration trials.
Page last updated March 20, 2023